Glaukos Corporation (GKOS) Key Metrics

NYSE: GKOSValuation, returns, debt and efficiency ratios over 10 years.

GKOS valuation today

Trailing 12 months · as of October 17, 2026
Market cap
$9.72B
Enterprise value
$8.87B
P/E (TTM)
—
Forward P/E
—
PEG ratio
1.64
Price / sales
15.9
10-yr median 10.9
Price / book
13.3
10-yr median 7.4
EV / EBITDA
—
Dividend yield
—
Beta
0.69

GKOS key metrics, 2016–2025

Fiscal year ended December 31, 2025 · U.S. dollars

GKOS valuation Price multiples at each fiscal year-end price.

Price / sales−38.3%
12.7
2025 · hover or tap a bar for each year
2016: 10.9 (+81.7%)2017: 5.5 (−49.3%)2018: 10.9 (+97.6%)2019: 9.5 (−13.6%)2020: 14.9 (+57.4%)2021: 7.0 (−52.9%)2022: 7.3 (+4.4%)2023: 12.2 (+67.0%)2024: 20.6 (+68.6%)2025: 12.7 (−38.3%)
20162025
Price / book−4.6%
9.8
2025 · hover or tap a bar for each year
2016: 10.7 (+135.3%)2017: 6.4 (−40.2%)2018: 11.4 (+78.8%)2019: 3.3 (−70.8%)2020: 5.0 (+50.7%)2021: 3.5 (−30.0%)2022: 3.9 (+11.3%)2023: 8.3 (+113.2%)2024: 10.3 (+23.7%)2025: 9.8 (−4.6%)
20162025
Free cash flow yield0.0 pts
−0.8%
2025 · hover or tap a bar for each year
2016: 0.5% (+1.2 pts)2017: 2.2% (+1.7 pts)2018: 0.4% (−1.7 pts)2019: −0.2% (−0.7 pts)2020: −0.9% (−0.7 pts)2021: −1.1% (−0.2 pts)2022: −3.1% (−1.9 pts)2023: −2.0% (+1.0 pts)2024: −0.9% (+1.2 pts)2025: −0.8% (0.0 pts)
20162025

GKOS valuation history

Fiscal year-endToday10-year median

GKOS returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

GKOS debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

GKOS cash returned to shareholders

DividendsBuybacksFree cash flow

GKOS price vs earnings per share

Share price at year-endEPS (right axis)

GKOS key metrics

2016–2025
Glaukos Corporation key metrics by fiscal year
2025202420232022202120202019201820172016
Valuation
Market capitalization$6.46B$7.91B$3.85B$2.07B$2.06B$3.35B$2.24B$1.98B$881.9M$1.25B
Enterprise value$6.32B$7.69B$3.94B$2.10B$2.03B$3.22B$2.14B$1.84B$762.9M$1.15B
P/E ratio——————145.3——276.5
Price / sales12.720.612.27.37.014.99.510.95.510.9
Price / book9.810.38.33.93.55.03.311.46.410.7
Price / free cash flow———————232.045.9207.4
Price / operating cash flow————83.5——105.234.6101.6
EV / sales12.520.112.57.46.914.39.010.24.810.1
EV / EBITDA————————139.1128.8
EV / free cash flow———————215.639.7191.5
Earnings yield−2.9%−1.9%−3.5%−4.8%−2.4%−3.6%0.7%−0.7%−0.0%0.4%
Free cash flow yield−0.8%−0.9%−2.0%−3.1%−1.1%−0.9%−0.2%0.4%2.2%0.5%
Dividend yield———0.3%1.3%7.8%0.6%—0.0%0.0%
Shareholder yield (dividends + buybacks)—0.1%0.1%0.4%1.5%8.0%0.8%0.0%0.0%0.0%
Share price at fiscal year-end$112.91$149.94$79.49$43.68$44.44$75.26$54.47$56.17$25.65$34.30
Per share
Revenue per share$8.87$7.27$6.50$5.96$6.33$5.06$5.76$5.13$4.63$3.14
Earnings per share−$3.28−$2.77−$2.78−$2.09−$1.07−$2.70$0.37−$0.37−$0.00$0.12
Operating cash flow per share−$0.81−$1.16−$1.19−$0.70$0.53−$0.52−$0.01$0.53$0.74$0.34
Free cash flow per share−$0.94−$1.28−$1.61−$1.34−$0.50−$0.67−$0.12$0.24$0.56$0.17
Cash per share$4.87$6.05$6.10$7.43$8.92$9.09$4.23$3.98$3.46$2.63
Book value per share$11.47$14.54$9.53$11.17$12.65$15.00$16.36$4.92$4.02$3.22
Tangible book value per share$7.83$8.29$2.33$3.29$4.05$5.48$5.46$4.92$3.93$3.04
Dividends per share———$0.14$0.59$5.90$0.31—$0.00$0.00
Capex per share$0.13$0.12$0.42$0.64$1.03$0.16$0.11$0.29$0.18$0.17
Debt per share$2.44$1.96$7.92$8.07$8.26$6.11$1.77—$0.00$0.00
Shares outstanding57.2M52.8M48.4M47.4M46.4M44.5M41.1M35.3M34.4M36.5M
Change in shares outstanding+8.4%+8.9%+2.1%+2.2%+4.3%+8.1%+16.5%+2.7%−5.7%+108.6%
Returns & profitability
Return on equity (ROE)−26.4%−23.8%−27.2%−17.8%−7.9%−18.0%3.6%−8.3%−0.1%4.3%
Return on invested capital (ROIC)−12.8%−17.6%−18.3%−11.6%−4.8%−17.6%−13.1%−39.1%−5.6%23.8%
Return on assets (ROA)−20.1%−15.3%−13.4%−9.0%−4.6%−13.2%3.0%−6.9%−0.1%3.6%
Return on tangible assets−27.4%−22.7%−22.8%−14.2%−6.8%−20.7%4.2%−6.3%−0.1%3.5%
Free cash flow margin−10.6%−17.6%−24.8%−22.4%−7.8%−13.3%−2.1%4.7%12.1%5.3%
Income quality (OCF / net income)——————−0.02——2.72
Financial health
Total debt$139.6M$103.4M$383.7M$382.9M$383.4M$272.0M$72.6M—$0$0
Cash & short-term investments$278.8M$318.9M$295.4M$352.7M$414.1M$404.4M$174.0M$140.5M$119.0M$95.8M
Net debt−$139.1M−$215.5M$88.3M$30.2M−$30.7M−$132.4M−$101.4M−$140.5M−$119.0M−$95.8M
Debt / equity0.210.130.830.720.650.410.11—0.000.00
Debt / assets0.160.110.410.360.340.270.09—0.000.00
Net debt / EBITDA————————−21.71−10.68
Current ratio4.695.995.346.137.679.454.565.815.587.09
Quick ratio4.065.224.785.617.319.133.825.385.166.68
Interest coverage-18.7-12.2-9.4-6.0-2.5-8.8-19.6—-51.87.0
Working capital$373.7M$374.7M$321.4M$371.5M$422.8M$419.7M$205.2M$146.2M$122.7M$103.1M
Invested capital$517.0M$551.4M$550.1M$560.2M$556.5M$535.1M$571.9M$33.4M$19.2M$21.5M
Tangible asset value$447.5M$437.4M$112.7M$156.0M$188.2M$243.6M$224.5M$173.9M$135.1M$110.7M
Net current asset value$237.7M$242.0M−$83.2M−$100.3M−$55.5M$131.4M$117.8M$143.5M$121.8M$102.9M
Graham number——————$11.75——$3.00
Graham net-net per share$2.70$3.52−$2.73−$3.07−$1.96$2.28$1.92$3.62$3.18$2.55
Capital allocation
Dividends paid———$6.5M$27.3M$262.5M$12.9M—$0$0
Share buybacks (net)—$6.6M$3.3M$2.7M$3.7M$3.9M$5.6M$587,000$0$0
Dividend payout ratio——————83.3%——0.0%
Dividends + buybacks / free cash flow———————6.9%0.0%0.0%
Capex / revenue1.5%1.6%6.4%10.7%16.3%3.1%2.0%5.7%4.0%5.5%
Capex / operating cash flow————193.4%——54.7%24.7%51.0%
Capex / depreciation0.180.160.530.841.390.200.481.651.151.33
Stock-based compensation / revenue12.5%13.1%13.8%13.6%10.3%20.7%15.4%14.2%11.0%7.7%
R&D / revenue29.7%35.6%44.1%43.6%34.4%38.0%28.8%27.4%24.4%25.5%
SG&A / revenue65.4%68.5%71.2%67.3%60.6%76.2%74.5%66.9%60.4%56.6%
Efficiency
Days sales outstanding60.947.944.044.843.160.444.035.635.534.9
Days of inventory on hand193.7193.4192.8161.0106.3116.2264.2178.3156.6123.4
Days payables outstanding60.251.467.257.532.120.257.191.279.974.4
Cash conversion cycle (days)194.5189.9169.6148.3117.4156.4251.1122.7112.383.9
Receivables turnover5.997.628.298.148.466.048.3010.2610.2910.47
Payables turnover6.077.115.436.3511.3918.076.404.004.574.91
Inventory turnover1.881.891.892.273.433.141.382.052.332.96
Asset turnover0.540.400.310.260.280.250.460.971.060.91
Average receivables$84.7M$50.3M$38.0M$34.8M$34.7M$37.2M$28.5M$17.7M$15.5M$10.9M
Average payables$18.8M$13.2M$13.9M$10.9M$5.9M$5.1M$6.0M$6.3M$4.6M$3.3M
Average inventory$60.6M$49.8M$39.9M$30.4M$19.4M$29.2M$27.9M$12.3M$9.0M$5.5M
Intangibles / total assets23.3%33.8%37.1%34.8%35.3%42.2%54.8%0.0%1.9%4.9%

Computed from GKOS's annual financial statements (latest annual report filed February 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

GKOS valuation and financial ratios

Glaukos earned a return on equity of −26.4% and a return on invested capital of −12.8% in fiscal 2025. It ended the year with $139.6 million of debt and $278.8 million in cash and short-term investments, a net cash position of $139.1 million. The share count rose 56.9% from 36.5M to 57.2M over 9 years.

See the GKOS income statement, the GKOS chart for price history, or the GKOS stock overview for the latest quote and news.

GKOS key metrics FAQ

What is Glaukos's return on equity?

Glaukos's return on equity (ROE) was −26.4% in fiscal 2025: net income of -$187.7 million on average shareholders' equity of $711.5 million.

What is Glaukos's ROIC?

Glaukos's return on invested capital was −12.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does Glaukos have?

Glaukos had total debt of $139.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.21 and more cash than debt.

What is Glaukos's free cash flow yield?

Glaukos generated -$54.0 million of free cash flow in fiscal 2025, a free cash flow yield of −0.8% on its market value at year-end ($6.5 billion).

What is Glaukos's current ratio?

Glaukos's current ratio was 4.69 at the end of fiscal 2025: current assets were 4.69 times current liabilities.

Medical Devices key metrics